Toggle light / dark theme

Human-Autonomy Interaction, Collaboration and Trust — Dr. Julie Marble, JHU Applied Physics Laboratory (APL)


Dr. Julie Marble is a senior scientist at the Johns Hopkins University Applied Physics Laboratory (JHUAPL) leading research in human-autonomy interaction, collaboration and trust.

Dr. Marble earned her PhD in Human Factors/Cognitive Psychology from Purdue University. After graduating from Purdue University, she joined the Idaho National Laboratory (INL), one of the national laboratories of the United States Department of Energy involved in nuclear research, first in the Human Factors group and then the Human and Robotic Systems group.

Following INL, she joined Sentient Corporation, where as CEO she led a DARPA Broad Agency Announcement BAA on Neuro-Technology for Intelligence Analysts and led research on to develop an intelligent decision aid to perform just-in-time maintenance on Navy helicopters.

Dr. Marble then worked as a Senior Scientist at the US Nuclear Regulatory Commission leading international and US studies on Human-Reliability Analysis methods in this vital domain and related to this, she is internationally recognized for her work, and is co-author of the SPAR-H method (Standardized Plant Analysis Risk Human Reliability Analysis), the most commonly used method of human reliability analysis in the US. She is also co-developer of the Cultural Affective Model, which integrates cultural impacts into human reliability in order to predict operator behavior.

DARPA’s Operational Fires (OpFires) program, which is developing a ground-launched intermediate-range hypersonic weapons system, is advancing to a new phase. Phase 3b will involve full-scale missile fabrication, assembly, and flight testing from a launch vehicle. Lockheed Martin Missiles and Fire Control was awarded this new contract modification after leading a successful Phase 3a integrated system preliminary design review that resulted in a comprehensive design and test plan.

The U.S. military routinely deploys throughout the world where warfighters can potentially be exposed to regional endemic diseases as well as chemical, biological, radiological, or nuclear (CBRN) threats. Rapid access to medical countermeasures (MCMs) against these threats is critical to protect Defense Department (DoD) personnel and local populations; however, manufacturing, stockpiling, and distribution issues remain.

Facilitating Novel Health-Tech and Bio-Medical Innovations For Over 9 Million Veterans — Dr. Rachel Ramoni, Chief of R&D, U.S. Department of Veterans Affairs.


Dr. Rachel Ramoni, is the Chief Research and Development Officer of the United States Department of Veterans Affairs (VA), where she oversees their nationwide research enterprise, encompassing some 2000 active projects, at more than 100 sites, with a total budget of $2 billion in both direct VA support, and research funding from outside entities such as the National Institutes of Health, other federal agencies, and nonprofit and private organizations.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides comprehensive healthcare services to military veterans at over 1000 VA medical centers and outpatient clinics located throughout the US – It also provides several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members.

The VA serves over 9 million enrolled Veterans each year, employs over 377000 people with an annual budget of $200 billion.

Dr. Ramoni earned a Doctor of Medicine in Dentistry degree from the Harvard School of Dental Medicine, as well as a Master of Science and Doctor of Science in epidemiology from the Harvard School of Public Health.